Mural Oncology plc (NasdaqGM: MURA)
Health Care · Biotechnology · IE
$—
— today · — 1Y
Mural Oncology plc (NasdaqGM: MURA) operates in the Biotechnology industry within the Health Care sector.
trading between 1.53 and 2.12.
Tweenvest scores Mural Oncology plc across four factors: quality 26/100. Its strongest factor is quality.
MURA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -6.93
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $2.12
- 52-week low
- $1.53
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 116
- Next earnings
- —
About Mural Oncology plc
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
- Founded
- 2017
- Listed since
- Nov 16, 2023
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.